Spyre Therapeutics (SYRE) net assets (shareholders' equity)

Net assets · fiscal 2025
$715.24M

Spyre Therapeutics (SYRE) had net assets of $715.24M at the end of fiscal 2025 (December 31, 2025). That is 38.1% higher than the $517.80M of fiscal 2024. Figures as of 18 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$715.24M
Change on fiscal 2024
+38.1%
Growth, 5 years
+38.6% a year
Highest on record
$715.24Mfiscal 2025
Lowest on record
-$22.21Mfiscal 2015
Fiscal years on record
122014–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Spyre Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 38.6% a year. Across the 12 fiscal years on record (2014–2025), the highest was $715.24M in fiscal 2025 and the lowest -$22.21M in fiscal 2015.

History · 12 fiscal years

Net assets by fiscal year

Spyre Therapeutics net assets (shareholders' equity), year by year

Spyre Therapeutics (SYRE) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$715.24M 38.1% up
2024$517.80M 181.4% up
2023$184.02M 265.8% up
2022$50.31M 40.1% down
2021$83.94M 40.0% down
2020$139.83M 132.7% up
2019$60.08M 10.9% down
2018$67.43M 34.0% up
2017$50.34M 20.1% down
2016$62.97M—
2015-$22.21M—
2014-$11.47M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Spyre Therapeutics and comparable companies
CompanyNet assetsFiscal year
Vaxcyte PCVX$2.69B2025
Bio-Rad Laboratories BIO$7.45B2025
Molina Healthcare MOH$4.07B2025
Spyre Therapeutics SYRE$715.24M2025
Qiagen QGEN$3.78B2025
Insulet PODD$1.52B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on SYRE

Spyre Therapeutics, figure by figure

Spyre Therapeutics (SYRE) overview: price, valuation and scorecardAll health care companies by market value

Spyre Therapeutics net assets (shareholders' equity): questions and answers

What are Spyre Therapeutics's net assets?

Spyre Therapeutics (SYRE) had net assets of $715.24M at the end of fiscal 2025 (December 31, 2025). That is 38.1% higher than the $517.80M of fiscal 2024.

What is the growth rate of Spyre Therapeutics's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 38.6% a year.

What are the highest and lowest net assets figures on record for Spyre Therapeutics?

Across the 12 fiscal years on record (2014–2025), the highest was $715.24M in fiscal 2025 and the lowest -$22.21M in fiscal 2015.

How is Spyre Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Spyre Therapeutics it is on record here for 12 fiscal years, 2014 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Spyre Therapeutics (SYRE) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/SYRE/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.